1392429-79-6 Usage
Uses
Used in Pharmaceutical Industry:
BI 882370 is used as an anticancer agent for targeting B-RAF-mutant melanoma and colorectal carcinoma. It inhibits the proliferation of human B-RAF-mutant melanoma cells and reduces tumor growth in mouse xenograft models, making it a promising candidate for cancer treatment.
Additionally, BI 882370 is used in combination therapies with trametinib for inducing tumor regression in A375 melanoma mouse xenograft models, showcasing its potential in overcoming resistance and enhancing treatment efficacy.
Check Digit Verification of cas no
The CAS Registry Mumber 1392429-79-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,9,2,4,2 and 9 respectively; the second part has 2 digits, 7 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1392429-79:
(9*1)+(8*3)+(7*9)+(6*2)+(5*4)+(4*2)+(3*9)+(2*7)+(1*9)=186
186 % 10 = 6
So 1392429-79-6 is a valid CAS Registry Number.
1392429-79-6Relevant articles and documents
CRYSTALLINE SALTS OF A B-RAF KINASE INHIBITOR
-
Page/Page column 50; 52; 53, (2019/05/15)
The present invention is related to crystalline salts of N-(3-(5-((1-ethylpiperidin-4-yl)(methyl)amino)-3-(pyrimidin-5-yl)-1H-pyrrolo[3,2-b]pyridin-1-yl)-2,4-difluorophenyl)propane-1-sulfonamide, a RAF kinase Inhibitor, useful in the treatment of cancer and other diseases.
NEW AZAINDOLYLPHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS
-
Page/Page column 65, (2012/08/27)
The present invention encompasses compounds of general formula (I) wherein the groups R2 to R6, A, X, Y and m are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain compounds of this kind and their use as medicaments.